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  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Sensitif 7 63.6 63.6 63.6 
  Resisten 4 36.4 36.4 100.0 




  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Sensitif 2 18.2 18.2 18.2 
  Resisten 9 81.8 81.8 100.0 
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  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Sensitif 8 44.4 44.4 44.4 
  Intermediet 2 11.1 11.1 55.6 
  Resisten 8 44.4 44.4 100.0 















  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Sensitif 5 27.8 27.8 27.8 
  Resisten 13 72.2 72.2 100.0 




  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Sensitif 9 56.3 56.3 56.3 
Intermediet 2 12.5 12.5 68.8 
Resisten 5 31.3 31.3 100.0 




  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Sensitif 8 50.0 50.0 50.0 
  Resisten 8 50.0 50.0 100.0 




  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Sensitif 10 90.9 90.9 90.9 
  Resisten 1 9.1 9.1 100.0 
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